Frontlight ResearchEarly access
Enrolling by invitationPhase 4
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
Key facts
- Who runs it
- Allievex Corporation
- Where
- Oakland and Pittsburgh, United StatesSee the 2 sitesAlso in 4 other countries, 4 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 15 people, planned
- Started
- 2 Dec 2022
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- AX 250
- Record updated
- 9 August 2023
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Must have completed 240 weeks of Study 250-202 and enter 250-401 within 8 weeks of dosing completion
- Provides written informed consent from parent or legal guardian and assent from subject, if required
- Has the ability to comply with protocol requirements in the opinion of the investigator
- If female with childbearing potential, must have a negative pregnancy test at the Screening visit and be willing to have additional pregnancy tests during the study
Who cannot take part
- Has received stem cell, gene therapy or enzyme replacement therapy (other than AX 250) for MPS IIIB
- Is prone to complications from ICV drug administration including patients with hydrocephalus or ventricular shunts
- Has received any investigational medication within 30 days prior to the Baseline visit or is scheduled to receive any investigational drug during the course of the study
- Has a history of poorly controlled seizure disorder
- Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with protocol requirements, the subject's well-being or safety, or the interpretability of the subject's clinical data
- Has (1) a cognitive age equivalent (AEq ) score ≤ 18 months, (2) a development quotient (DQ) score ≤ 20, and (3) no evidence of improvement during the 250-202 study in secondary or exploratory efficacy endpoints
- Would not benefit from enrolling in the study in the opinion of the investigator
Where in United States
Also in 4 other countries, 4 sites
- UCSF Benioff Children's Hospital OaklandOakland, United StatesEnrolling by invitation
- UPMC Children's Hospital PittburghPittsburgh, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is a Phase 3B/4, multicenter, multinational, open label study to further evaluate intracerebroventricular (ICV) delivered AX 250 treatment in MPS IIIB subjects that complete Study 250-202 for up to an additional 3 years (144 weeks) of treatment with AX 250 administered by ICV infusion every other week. Subjects will be evaluated for neurocognitive function, communication, adaptive behavior, quality of life, imaging characteristics and biochemical markers of disease burden. Safety will be assessed by adverse events, clinical labs, and physical exams.
The group in the trial
- single armTreatment being tested
AX 250 300 mg - open label
Treatment: AX 250
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Open-Label Multicenter Extension Study to Further Evaluate Safety, Tolerability and Efficacy of Intracerebroventricular AX 250 Treatment in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) Patients
- Record updated
- 9 August 2023